浅析“十三五”期间鼓励药品创新政策的发展变化  

Analysis on the Changes of Policies to Encourage Drug Innovation During the 13th Five-Year Plan Period

作　　者：王婧璨 张宁[1] 蒲嘉琪 WANG Jing-can;ZHANG Ning;PU Jia-qi(Center For Drug Evaluation,National Medical Products Administration)

机构地区：[1]国家药品监督管理局药品审评中心

出　　处：《中国食品药品监管》2021年第5期14-21,共8页China Food & Drug Administration Magazine

摘　　要：鼓励药品创新,是党中央、国务院为促进医药产业结构调整和技术创新、提高产业竞争力、满足公众临床需要的重要部署。“十三五”期间实施了多项鼓励药品创新的政策制度。本文简要介绍了鼓励药品创新制度的发展变化,分析各项制度的实施效果,并提出对下一步政策制定的思考。Encouraging drug innovations represents an important strategy of the CPC Central Committee and the State Council in promoting restructuring and technological innovation of the pharmaceutical industry,improving the competitiveness of the industry,and meeting the clinical needs of the public.A number of policies and regulations were implemented to promote drug innovation during the 13th Five-Year Plan period.This paper introduces the policy development and changes aimed to encourage drug innovation,analyzes the effects of policy implementation,and proposes suggestions for the design of follow-up policies.

关 键 词：鼓励药品创新 十三五 政策实施效果 政策变化 知识产权保护 

分 类 号：R95[医药卫生—药学]